• Offer for Industry
  • Young GI
  • Patients
  • Press
  • Newsletter
  • Contact us
UEG Connect
Create myUEG account
  • About
    • To landing page
      • Who we are
      • Boards, Committees & Groups
      • Governance
      • Headquarters Management
      • History
      • What we do
      • Strategic Drivers
      • Year in Review
      • Our Members
      • Specialist Member Societies
      • National Member Societies
      • UEG Community
      • UEG Associates
      • UEG Connect
      • Women in GI
      • Young GIs
      • Researchers
      • Event Calendar
  • Week
    • To landing page
      • Congress Resources
      • UEG Week Recordings ↗
      • CME Accreditation
      • Future UEG Week
      • Programme
      • Postgraduate Teaching
      • Industry
      • Supporters
  • Education
    • To landing page
      • Gutflix - Learning Platform ↗
      • Online Courses ↗
      • Mistakes in... ↗
      • UEG Podcast ↗
      • Webinars ↗
      • Summer School
      • Masterclass
      • Gut Guide
      • Career Development
      • CME in Europe
      • Supporters
  • Research
    • To landing page
      • Horizon Europe Support
      • Start-up Grant
      • Research Projects
      • HoloSurge
      • Intercept
      • InfoGut COST Action
      • White Book 2
      • Main Results
      • Full Reports
      • Materials and Presentations
  • Quality of Care
    • To landing page
      • Search Guidelines ↗
      • Non-English Guidelines
      • How to Develop Guidelines ↗
      • Quality of Care Initiatives
      • Quality Indicators
  • Public Affairs
    • To landing page
      • News
      • Focus Areas
      • Advocacy Toolbox
      • Stakeholder Collaboration
      • Digestive Health Month
      • Position Papers
      • Advocacy Bulletin
      • #EUNewsline
      • MEP Digestive Health Group
  • Publications
    • To landing page
      • Congress Publications
      • Research Publications
      • Public Affairs Publications
      • Education Publications
      • UEG Publications
      • UEG Journal ↗
      • UEG Journal Podcast ↗
  • Opportunities
    • To landing page
      • Top Abstract Prizes
      • National Scholar Award
      • Travel Grants
      • International Scholarship Awards
      • Research Prize
      • Research Fellowship
      • Lifetime Achievement Award
      • Journal Best Paper Award
      • Activities Endorsement
      • Rising Star Awards
      • Clinical Visiting Fellowships
      • Open Positions
      • Talent Pool
  • Gutflix ↗
  • Offer for Industry
  • Young GI
  • Patients
  • Press
  • Newsletter
  • Contact us
Decide on the Spot

Staining the liver

March 09, 2017 | Rui Castro

Although novel noninvasive means of diagnosis and staging for liver diseases are eagerly anticipated, histopathologic examination of liver biopsy samples remains a key procedure. For animal models of liver disease, histopathologic examination is one of the most important examination techniques.

At present there is no clear unifying pathogenic mechanism for nonalcoholic fatty liver disease (NAFLD) progression, thus hampering the development of much-needed effective treatments and allowing nonalcoholic steatohepatitis (NASH) to advance to cirrhosis, end-stage liver failure and hepatocellular carcinoma (HCC).1,2 As such, our laboratory is building on its work using a NASH–HCC mouse model of NAFLD that replicates the pathological progression from steatosis and NASH to fibrosis and HCC.

In the images shown, you can see several representative histological views of mouse liver biopsy samples taken from our NASH–HCC model—both controls and different disease-stage specimens. The samples have been stained with either hematoxylin and eosin (H&E) or Masson’s trichrome stains. Although generally used to analyse tissue morphology and identify the presence of liver cirrhosis, respectively, these dyes further allow the visualization of additional useful characteristics, as depicted here. For this reason, they are routinely used in the study of virtually every animal model of liver disease.

Case Question 1

Which histopathological features may be identified in the liver with the h&e and masson’s trichome stains?

a.     Intracellular inclusions

b.     Liver architecture, steatosis and fibrosis

c.     Ceroid-laden macrophages

d.     All the above

 

  • Case question 1 answer and discussion
Case question 1 answer and discussion

Correct answer: d.

Discussion

Hematoxylin has a deep blue-purple colour and stains nucleic acids, while eosin is pink and stains proteins in a nonspecific manner. Liver specimens stained with H&E will, therefore, typically display blue nuclei, with the cytoplasm and extracellular matrix in different shades of pink. Masson’s trichrome stain is commonly used in parallel with the H&E stain to examine liver specimens. With this method, the three dyes are used selectively to stain collagen (in blue), muscles, erythrocytes, fibrin and cytoplasm (in red), with nuclei often stained black. 

For both stains, control mice (figures 1 and 2) show normal liver architecture and cellular integrity with no fibrosis. Of note, because Masson’s trichrome stains type 1 collagen, portal tracts and vessel walls will also be stained blue, although not necessarily representing reactive fibrosis (figure 2).

Hepatocellular steatosis can be identified by either the presence of single large fat droplets, alongside nuclei dislocation to the cell’s periphery (macrovesicular steatosis), or small lipid droplets and no nuclei displacement (microvesicular steatosis). The former is typical of NAFLD and associates with inflammation in NASH (figure 3). Steatosis may also be observed concomitantly with fibrosis, whose characteristic pattern in NASH is perisinusoidal/pericellular (‘chicken wire’) (figure 4). In more advanced stages of fibrosis, collagen fibres become thicker and form a more widespread network (figure 5). While cirrhosis appears to be absent (inconclusive evidence of extensive scar tissue, inflammatory infiltrates and the presence of regenerative micronodules), it should not be excluded; alternative staining and/or capturing additional images at 100x magnification would be needed to reach a definite conclusion.

During the course of NASH–HCC, typical hepatocellular cytoplasmic (figure 6) and nuclear (figure 7) alterations occur, including cytoplasmic accumulation of protein droplets, lipofuscin, ceroid, copper and iron. Furthermore, in HCC, liver architecture and cellular integrity is severely compromised (figure 8). Here we can note the presence of broad trabeculae and irregular nuclear contours.

Lipofuscin or ceroid is a yellow-brown product considered to represent a lipid breakdown product of cell membranes that accumulates in Kupffer cells and macrophages as a result of hepatocyte necrosis and/or apoptosis. Foci of ceroid-laden macrophages are common in liver fibrosis (figure 9), although their pathological significance remains poorly explored.3 As for protein accumulation, the most common intracellular inclusions comprise Mallory–Denk bodies (MDB; mainly composed of keratin (K) 8, K18, p62 and ubiquitin) and intracellular hyaline bodies (IHB; composed of p62 and/or ubiquitin). A recent study has shown that HCC patients who have liver IHB inclusions have a poor prognosis.4

References

  1. Starley BQ, Calcagno CJ and Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820–1832. http://onlinelibrary.wiley.com/doi/10.1002/hep.23594/epdf
  2. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017; 37 (Suppl 1): 81–84. http://onlinelibrary.wiley.com/doi/10.1111/liv.13299/epdf
  3. Rantakari P, Patten DA, Valtonen J, et al. Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury. Proc Natl Acad Sci USA 2016; 113: 9298-9303. http://www.pnas.org/content/113/33/9298.long
  4. Aigelsreiter A, Neumann J, Pichler M, et al. Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis. Liver Int Epub ahead of print 25 November 2016. DOI: 10.1111/liv.13325. http://onlinelibrary.wiley.com/doi/10.1111/liv.13325/abstract
Social Sharing
  • About the Author
  • Further UEG Resources
About the Author

Dr Rui Castro is currently a Principal Investigator at the Research Institute for Medicines (iMed.ULisboa), Portugal. He completed his PhD at the University of Lisbon and the Department of Medicine (GI Division), University of Minnesota Medical School, USA, in 2006. Since then, Dr Castro has been combining his background on the modulation of liver cell function with his most recent discoveries in the miRNA field, to answer key questions on liver physiology and pathophysiology, while supervising both undergraduate and postgraduate students under the GI umbrella. In 2015, he was selected as a UEG Rising Star. Follow Rui on Twitter @RuiCastroHD.

Further UEG Resources
  • ‘Pathology of GI-cancer mice models’ presentation at UEG Basic Science Course 2016.
  •  ‘The role of liver biopsy in NAFLD’ presentation at UEG Week 2012. 

Comment

1 comment(s) to "Staining the liver"
  • skola Davis
    May 21, 2020
    Two years ago, I learnt about a successful HEPATITIS B Virus treatment from Herbal Health Point (w w w. herbalhealthpoint. c om), I was on the treatment for over 7 months and tested negative after I completed the treatment. I completed the treatment two years ago and still negative!

Please log in with your myUEG account to post comments.

Related Articles
Mistakes in...
Mistakes in hepatitis C and how to avoid them
Mistakes in...
Mistakes in cholangioscopy and how to avoid them
Press Release
Alcohol Labelling: Why Are Citizens Denied the Right to Know?
Press Release
Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes
Latest Articles
Decide on the Spot
An elusive lesion in the colon
Decide on the Spot
A rare biopsy finding with many possible causes
Decide on the Spot
An incidental diagnosis by endoscopic ultrasound
Decide on the Spot
A not-so-black-and-white case of gastrointestinal bleeding
Get our newsletter!
Sign up with your email to receive UEG news and updates. We respect your privacy.

Headquarters Management

United European Gastroenterology

Wickenburggasse 1
1080 Vienna, Austria



T: +43 1 997 1639

UEG Week Registration

Mondial Congress & Events

Official UEG Week Registration Partner
Operngasse 20b
1040 Vienna, Austria



T: +43 1 58804 - 0

More

Imprint

Terms & Conditions

Media Policies

Privacy Policy

Change cookie-settings

Social Media

7 767 Followers

23 000 Followers

15 666 Followers

5 866 Followers

3 670 Subscribers

11 399 Subscribers

65 Subscribers

409 Subscribers

UEG copyright 2025. All rights reserved. Use of this website constitutes acceptance of the Privacy Policy and Terms & Conditions.